← All trials
NCT05068752
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 28, 2021
- Primary completion
- Sep 30, 2022
- Completion date
- Sep 30, 2023
- First posted
- Oct 6, 2021
- Last posted
- Nov 3, 2021
- Enrollment
- 12
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- HonorHealth Research InstituteLead sponsor
- BayerCollaborator
- GenentechCollaborator
- HonorHealth Research InstituteOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.